Cholinesterase Inhibitors Improve Both Memory and Complex Learning in Aged Beagle Dogs

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Alzheimer's Disease

• Publication date

  2011-08-26

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.3233/JAD-2011-110005PMID 21593569PMCID PMC4979003
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phenserine Efficacy in Alzheimer's Disease

  2011cited by this paper
• Aged dogs demonstrate both increased sensitivity to scopolamine impairment and decreased muscarinic receptor density.

  2011cited by this paper
• Why so few drugs for Alzheimer's disease? Are methods failing drugs?

  2010cited by this paper
• Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease.

  2008cited by this paper
• The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant-conditioning memory tasks for screening drug candidates

  2008cited by this paper
• Region specific neuron loss in the aged canine hippocampus is reduced by enrichment.

  2008cited by this paper
• Animal Models of Alzheimer's Disease: Therapeutic Implications

  2008cited by this paper
• A Two-Year Study with Fibrillar β-Amyloid (Aβ) Immunization in Aged Canines: Effects on Cognitive Function and Brain Aβ

  2008cited by this paper
• Cholinergic treatments with emphasis on M1 muscarinic agonists as potential disease-modifying agents for Alzheimer’s disease

  2008cited by this paper
• The Canine (Dog) Model of Human Aging and Disease: Dietary, Environmental and Immunotherapy Approaches

  2008cited by this paper
• Estimation of Working Memory in Macaques for Studying Drugs for the Treatment of Cognitive Disorders

  2008cited by this paper
• Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease

  2008cited by this paper
• The Experimental Alzheimer's Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-β Peptide Levels in Cell Culture and Mice

  2007cited by this paper
• Anti-dementia drugs and hippocampal-dependent memory in rodents

  2007cited by this paper
• Soluble beta-amyloid[25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning.

  2007cited by this paper
• Phenserine

  2007cited by this paper
• Neurogenesis decreases with age in the canine hippocampus and correlates with cognitive function.

  2007cited by this paper
• Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys

  2007cited by this paper
• A specific amyloid-β protein assembly in the brain impairs memory

  2006cited by this paper
• A specific amyloid-beta protein assembly in the brain impairs memory.

  2006cited by this paper
• Application of an automated voxel-based morphometry technique to assess regional gray and white matter brain atrophy in a canine model of aging

  2006cited by this paper
• Therapeutic options for cognitive decline in senior pets.

  2006cited by this paper
• Diffuse beta-amyloid plaques and hyperphosphorylated tau are unrelated processes in aged dogs with behavioral deficits

  2006cited by this paper
• Identification of Novel Small Molecule Inhibitors of Amyloid Precursor Protein Synthesis as a Route to Lower Alzheimer's Disease Amyloid-β Peptide

  2006cited by this paper
• Visuospatial function in the beagle dog: an early marker of cognitive decline in a model of human aging and dementia.

  2006cited by this paper
• Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide.

  2006cited by this paper
• Neuroprotective effects of cognitive enrichment.

  2006cited by this paper
• Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging.

  2005cited by this paper
• Phenserine: a physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze

  2005cited by this paper
• Behavior problems in geriatric pets.

  2005cited by this paper
• Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans.

  2005cited by this paper
• The cholinesterase inhibitor, phenserine, improves Morris water maze performance of scopolamine-treated rats.

  2005cited by this paper
• Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects.

  2005cited by this paper
• The canine model of human cognitive aging and dementia: pharmacological validity of the model for assessment of human cognitive-enhancing drugs.

  2005cited by this paper
• Assessment of nutritional interventions for modification of age-associated cognitive decline using a canine model of human aging

  2005cited by this paper
• An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.

  2005cited by this paper
• The Integrated Role of Desferrioxamine and Phenserine Targeted to an Iron‐Responsive Element in the APP‐mRNA 5′‐Untranslated Region

  2004cited by this paper
• Dose-specific effects of scopolamine on canine cognition: Impairment of visuospatial memory, but not visuospatial discrimination

  2004cited by this paper
• Scopolamine challenges in Alzheimer's disease

  2004cited by this paper
• Learning ability in aged beagle dogs is preserved by behavioral enrichment and dietary fortification: a two-year longitudinal study.

  2004influential reference
• Frontal lobe volume, function, and beta-amyloid pathology in a canine model of aging.

  2004cited by this paper
• Role of acetylcholinesterase inhibitors in the metabolism of amyloid precursor protein.

  2003cited by this paper
• Size and reversal learning in the beagle dog as a measure of executive function and inhibitory control in aging.

  2003cited by this paper
• Effects of age on measures of complex working memory span in the beagle dog (Canis familiaris) using two versions of a spatial list learning paradigm.

  2003cited by this paper
• Current treatments for Alzheimer's disease: cholinesterase inhibitors.

  2003cited by this paper
• Locomotor activity rhythms in dogs vary with age and cognitive status.

  2003cited by this paper
• Loss of muscarinic M4 receptors in hippocampus of Alzheimer patients.

  2003cited by this paper
• Dietary enrichment counteracts age-associated cognitive dysfunction in canines.

  2002cited by this paper
• Visuospatial impairments in aged canines (Canis familiaris): the role of cognitive-behavioral flexibility.

  2002influential reference
• Oxidative damage increases with age in a canine model of human brain aging

  2002cited by this paper
• Donepezil reverses a mnemonic deficit produced by scopolamine but not by perforant path lesion or transient cerebral ischaemia

  2002cited by this paper
• Brain aging in the canine: a diet enriched in antioxidants reduces cognitive dysfunction.

  2002cited by this paper
• Effect of age and level of cognitive function on spontaneous and exploratory behaviors in the beagle dog.

  2001cited by this paper
• Phenserine regulates translation of β-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development

  2001cited by this paper
• Effects of amyloid-beta-(25-35) on passive avoidance, radial-arm maze learning and choline acetyltransferase activity in the rat.

  2001cited by this paper
• The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics

  2000cited by this paper
• The β-Amyloid Precursor Protein and its Derivatives: From Biology to Learning and Memory Processes

  2000cited by this paper
• Region-specific age at onset of β-amyloid in dogs☆ ☆

  2000cited by this paper
• Region-specific age at onset of beta-amyloid in dogs.

  2000cited by this paper
• Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease.

  2000cited by this paper
• The canine as a model of human cognitive aging: recent developments.

  2000cited by this paper
• Landmark discrimination learning in the dog.

  1999cited by this paper
• Correlation of the intrinsic clearance of donepezil (Aricept) between in vivo and in vitro studies in rat, dog and human.

  1999cited by this paper
• Visual-discrimination learning ability and beta-amyloid accumulation in the dog.

  1998cited by this paper
• Magnetic resonance imaging of anatomic and vascular characteristics in a canine model of human aging.

  1998cited by this paper
• Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14‐unit T‐maze induced by blockade of the N‐methyl‐D‐aspartate receptor

  1998cited by this paper
• Effects of the potassium channel blockers, apamin and 4-aminopyridine, on scopolamine-induced deficits in the delayed matching to position task in rats: a comparison with the cholinesterase inhibitor E2020

  1998cited by this paper
• Scopolamine model of dementia: electroencephalogram findings and cognitive performance

  1998cited by this paper
• Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys

  1997cited by this paper
• Possible role of the cholinergic system and disease models.

  1997cited by this paper
• Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease

  1997cited by this paper
• Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions.

  1997cited by this paper
• Diffuse plaques contain C-terminal A beta 42 and not A beta 40: evidence from cats and dogs.

  1996cited by this paper
• Effects of anticholinesterase drugs tacrine and E2020, the 5-HT(3) antagonist ondansetron, and the H(3) antagonist thioperamide, in models of cognition and cholinergic function.

  1996cited by this paper
• An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors.

  1996cited by this paper
• Diffuse plaques contain C-terminal Aβ42 and not Aβ40: Evidence from cats and dogs

  1996cited by this paper
• Beta-amyloid accumulation correlates with cognitive dysfunction in the aged canine.

  1996cited by this paper
• Spatial learning and memory as a function of age in the dog.

  1995cited by this paper
• Maze learning in aged rats is enhanced by phenserine, a novel anticholinesterase.

  1995cited by this paper
• Cognitive functions and aging in the dog: acquisition of nonspatial visual tasks.

  1994cited by this paper
• Rodent models of memory dysfunction in Alzheimer's disease and normal aging: moving beyond the cholinergic hypothesis.

  1994cited by this paper
• The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory.

  1993cited by this paper
• Central Anticholinergic Hypersensitivity in Aging

  1992cited by this paper
• Differential Alteration of Various Cholinergic Markers in Cortical and Subcortical Regions of Human Brain in Alzheimer's Disease

  1988cited by this paper
• Decreased muscarinic receptor binding in cerebral cortex and hippocampus in Alzheimer's disease.

  1987cited by this paper
• Nicotinic and muscarinic cholinergic receptors in Alzheimer's disease and related disorders.

  1987cited by this paper
• Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study.

  1987cited by this paper
• Cholinergic receptors in aging and Alzheimer's disease.

  1986cited by this paper
• Pharmacologic modelling of Alzheimer's disease.

  1986cited by this paper
• Brain muscarinic receptors in senile dementia.

  1985cited by this paper
• Cognitive and behavioral sensitivity to scopolamine in Alzheimer patients and controls.

  1985cited by this paper
• Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases.

  1983cited by this paper
• The cholinergic hypothesis of geriatric memory dysfunction.

  1982cited by this paper
• Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

  1978cited by this paper
• CHANGES IN BRAIN CHOLINESTERASES IN SENILE DEMENTIA OF ALZHEIMER TYPE

  1978cited by this paper
• Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue.

  1977cited by this paper
• Necropsy evidence of central cholinergic deficits in senile dementia.

  1977cited by this paper
• Selective loss of central cholinergic neurons in Alzheimer's disease.

  1976cited by this paper
• Human memory and the cholinergic system. A relationship to aging?

  1974cited by this paper

• Evaluation of the safety and efficacy of a donepezil depot injection in dogs with canine cognitive dysfunction

  2025cites this paper
• Selection of five different types of animal models of Alzheimer’s disease: based on pathological similarity and research objectives

  2025cites this paper
• Cognition and modulation of the cholinergic system.

  2025cites this paper
• Recent advances in diagnostic and therapeutic strategies for canine cognitive dysfunction.

  2025cites this paper
• Feline Cognition and the Role of Nutrition: An Evolutionary Perspective and Historical Review

  2024cites this paper
• Comparative neurogenetics of dog behavior complements efforts towards human neuropsychiatric genetics

  2023cites this paper
• Regulatory Mechanisms in Biosystems

  2023cites this paper
• Side bias behaviour in dogs shows parallels to the hemispatial neglect syndrome

  2023cites this paper
• Potential revival of cholinesterase inhibitors as drugs in veterinary medicine

  2023influential citation
• Sphingolipids and DHA Improve Cognitive Deficits in Aged Beagle Dogs

  2022cites this paper
• Pharmacokinetics and Pharmacodynamic Effect of a Blood-Brain Barrier-Crossing Fusion Protein Therapeutic for Alzheimer’s Disease in Rat and Dog

  2022cites this paper
• Establishment of Level a In Vitro–In Vivo Correlation (IVIVC) via Extended DoE-IVIVC Model: A Donepezil Case Study

  2022cites this paper
• From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimer’s disease

  2021cites this paper
• Cognitive Dysfunction in Cats: Update on Neuropathological and Behavioural Changes Plus Clinical Management.

  2021cites this paper
• Translational animal models for Alzheimer's disease: An Alzheimer's Association Business Consortium Think Tank

  2020cites this paper
• Glucosylpolyphenols as inhibitors of Aβ-induced Fyn kinase activation and Tau phosphorylation: synthesis, membrane permeability, and exploratory target assessment within the scope of type 2 diabetes and Alzheimer's disease.

  2020cites this paper
• Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor

  2020cites this paper
• Long-Term Non Anesthetic Preclinical Study Available Extra-Cranial Brain Activator (ECBA) System for the Future Minimally Invasive Human Neuro Modulation

  2020cites this paper
• Canine Cognitive Dysfunction and Alzheimer’s Disease – Two Facets of the Same Disease?

  2019cites this paper
• The dog (Canis familiaris) as a translational model of autism: It is high time we move from promise to reality.

  2019cites this paper
• Computational and kinetic studies of acetylcholine esterase inhibition by (+)-phenserine.

  2019cites this paper
• Nigella sativa oil protected the hippocampus against Acetyl cholinesterase and oxidative dysfunctions-driven impaired working memory in rats

  2019cites this paper
• Computational Studies on Acetylcholinesterase Inhibitors: from Biochemistry to Chemistry.

  2019cites this paper
• Dichlorvos Induced AChE Inhibition in Discrete Brain Regions and the Neuro-Cognitive Implications: Ameliorative Effect of Nigella Sativa

  2018cites this paper
• New advances in pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors

  2018cites this paper
• The Aged Dog as a Natural Model of Alzheimer’s Disease Progression

  2017cites this paper
• Current Pharmacological and Non-pharmacological Approaches for Therapy of Feline and Canine Dementia

  2017cites this paper
• Carnivore concepts: Categorization in carnivores “bears” further study

  2017cites this paper
• Canine and Feline Dementia

  2017cites this paper
• Neurobehavioral deficits and brain oxidative stress induced by chronic low dose exposure of persistent organic pollutants mixture in adult female rat

  2016cites this paper
• Cognitive Impairments Induced by Concussive Mild Traumatic Brain Injury in Mouse Are Ameliorated by Treatment with Phenserine via Multiple Non-Cholinergic and Cholinergic Mechanisms

  2016cites this paper
• Response to stimulus relations by a dog (Canis lupus familiaris)

  2016cites this paper
• A novel mechanism for cognitive enhancement in aged dogs with the use of a calcium-buffering protein

  2015cites this paper
• Cognitive Subdomain Responses to Galantamine in Alzheimer’s Disease

  2014cites this paper
• Effects of Selective Activation of M1 and M4 Muscarinic Receptors on Object Recognition Memory Performance in Rats

  2014cites this paper
• Anticholinesterase Activities Of Selected Polyphenols – A Short Report

  2014cites this paper
• Enzyme Inhibitors Involved in the Treatment of Alzheimer’s Disease

  2014cites this paper
• Rapid improvement of canine cognitive dysfunction with immunotherapy designed for Alzheimer's disease.

  2013cites this paper
• Effects of selective allosteric activation of M 1 and M 4 muscarinic receptors on object recognition memory performance in rats

  2013cites this paper
• New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors.

  2013cites this paper
• Strategies, Development, and Pitfalls of Therapeutic Options for Alzheimer's Disease

  2012cites this paper
• Antioxidants in Down syndrome.

  2012cites this paper
• Aging biology: a new frontier for drug discovery

  2012cites this paper
• Cognitive dysfunction syndrome: a disease of canine and feline brain aging.

  2012cites this paper
• P4‐283: A novel mechanism for cognitive enhancement in aged dogs with the use of a calcium binding protein

  2011cites this paper